KING OF PRUSSIA, Pa., Jan. 05, 2017 -- Aspire Bariatrics, Inc., a commercial-stage medical-device company with a novel device for the treatment of obesity, announced today that Katherine D. Crothall, PhD, President & Chief Executive Officer, is scheduled to present at the 35th Annual JP Morgan Healthcare Conference in San Francisco at 11:30 AM PT on January 12.
About Aspire Bariatrics, Inc.
Aspire Bariatrics is a commercial-stage medical device company with a minimally-invasive, endoscopic device, the AspireAssist®, to treat obesity. In June 2016, the Company received premarket approval (PMA) from the FDA. AspireAssist Therapy is an alternative to bariatric surgery, providing comparable weight loss, but with far better safety, complete reversibility, and at a significantly lower cost than bariatric surgery. The therapy provides a holistic approach to patient development of improved eating behaviors, reflected in significant improvement in quality of life and high satisfaction with the therapy. www.aspirebariatrics.com.
Contact for Investors and Media Kathy Crothall, PhD President and CEO (610) 590-1568 kathy.crothall@aspirebariatrics.com
